Tauriga Sciences Inc. to Showcase TopiCanna Cream and Other Natural Wellness Products at the 2015 Northern California Cannabis Cup
LOS ANGELES, June 12, 2015 /PRNewswire/ -- Tauriga Sciences, Inc. (OTCQB: TAUG) or ("Tauriga" or "the Company"), a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, today announced that the Company will have a booth at the Northern California Cannabis Cup to be held in San Francisco, California on June 20-21, 2015 (http://www.cannabiscup.com/norcal/). Tauriga's booth at the event will feature the Company's cannabidiol (CBD) products, TopiCanna cream and CannaCaviar soft gels, as well as Tauriga's natural wellness supplements. Tauriga will also be marketing Breathe eCig Corp.'s second generation e-cigarettes at its booth, under a revenue sharing arrangement.
Both TopiCanna and CannaCaviar contain cannabidiol (CBD) oil from non-GMO industrial hemp that is grown without pesticides, herbicides, or chemical fertilizers. The oil has been lab tested for quality and is natural, safe and legal in the United States. CBD has been associated with many medicinal properties and therapeutic benefits, yet unlike THC, it does not create a psychoactive "high." Preclinical studies using animal models suggest that CBD has anticonvulsant, anxiolytic/anti-depressant, anti-inflammatory, antiemetic, and anti-oxidant properties. As such, CBD may have important therapeutic benefits in the treatment of a wide range of conditions, including chronic pain, neurodegenerative diseases, anxiety, nausea, cancer, arthritis, and other health concerns. Many who have used topical cannabis creams have reported decreased musculoskeletal pain. Company's non-cannabis containing natural supplements include IndiCalm, natural calming formula without inducing cognitive impairment; ClearNaze, a natural decongestant without stimulant or drowsiness effects; Satietiva, an amino acid-based appetite suppressant; and MendWCan, a highly pure, potent and palatable Omega 3 supplement. Information on Tauriga's natural wellness line may be found on the Company's e-commerce site, www.taurigastore.com.
Tauriga's Chairman & CEO Dr. Stella Sung stated, "The Northern California Cannabis Cup is an ideal forum to showcase the Company's products and provide information about the CBD e-cigarette currently being developed. We are looking forward to introducing our product line to new potential customers and distributors. We have been extremely pleased with the product feedback and testimonials we have already received, because it suggests we are using quality natural ingredients, such as CBD oil, amino acids, and botanicals to support well-being without narcotic effects. Our goal is to bring these benefits to as many people as possible."
Tauriga continues to work on strengthening its capital market profile. As part of these efforts, management has not drawn a salary since April and is working on behalf of its shareholders and toward its corporate mission to bring natural wellness and cleantech alternatives to improve the quality of lives.
About Tauriga Sciences, Inc.:
Tauriga Sciences, Inc. (TAUG) is a diversified life sciences company focused on generating profitable revenues in the natural wellness sector and in developing a proprietary synthetic biology platform technology. The mission of the Company is to acquire and build a diversified portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company's business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. Please visit the Company's corporate website at www.tauriga.com and the Company's e-commerce website at www.taurigastore.com.
NON SOLICITATION:
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.
DISCLAIMER:
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.
Food and Drug Administration Disclaimer: None of the statements contained in this press release regarding any of the products either offered or to be offered in the future by the Company have been evaluated by the Food and Drug Administration. Additionally, none of the products is intended to diagnose, treat, cure, or prevent any disease.
CONTACT:
Dr. Stella M. Sung,
Chairman and Chief Executive Officer
Tauriga Sciences, Inc.
www.tauriga.com
San Diego: + 1-858-353-5749
Montreal: +1-514-840-3697
Email: [email protected]
SOURCE Tauriga Sciences, Inc.
Share this article